Shun Jiang
Analyst · 86Research.
Thanks, Robert. So, as discussed, we issued around 15.6 million options to approximately 100 employees, quite a diverse claim. These employees predominantly were in the R&D teams, as well as certain management personnel, predominantly R&D focused personnel. In terms of the kind of the terms of these options or the incentive plan, as disclosed in our prospectus as well as the 20-F Annual Report, these are five-year vesting period, incentive plan with 40% of the amount issued matured after two years, so zero, after one year 40% up to three years, and then 20% for the next three years, accumulating for the entirety of the plan. The average strike price -- or the average kind of exercise price is around US$0.55 to US$1.1 per share, which translates into -- or translates into 1.65 to $3 or $3.30 per ADS. So, this is relatively in the money options. Small portion of these were vested. So, just over 1.5 million were vested immediately, so some back dated options to certain management employees that were hired few years earlier. I think, the overall impact on our share-based compensation expense line item, while outsized this quarter, should not be too different from what we have historically expensed. The historical SB expense was predominantly due to -- or predominantly arose from the amortization of our 2015 share option plan which has now largely been fully amortized. So, now, this 2018 share option plan is in essence replacing the 2015 share option plan. Now, in this particular quarter, the expense was slightly outsized due to the kind of the immediately amortized portion that were expensed kind of on a one-off basis. I think, over the second half of this year, you should expect around say RMB 40 million of SBC expenses in relation to the 2018 plan, subject to of course exchange rates or any forfeitures. So, on average, around RMB 20 million per quarter, and probably slightly decreasing over time, given the amortization schedule.